A detailed history of Tower Research Capital LLC (Trc) transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,033 shares of TPST stock, worth $5,309. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,033
Previous 15 40120.0%
Holding current value
$5,309
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.96 - $2.23 $5,777 - $13,420
6,018 Added 40120.0%
6,033 $8,000
Q2 2024

Aug 13, 2024

SELL
$2.01 - $5.44 $16,039 - $43,411
-7,980 Reduced 99.81%
15 $0
Q1 2024

May 15, 2024

BUY
$3.16 - $4.66 $21,864 - $32,242
6,919 Added 643.03%
7,995 $31,000
Q4 2023

Feb 13, 2024

SELL
$0.23 - $9.77 $2,841 - $120,718
-12,356 Reduced 91.99%
1,076 $4,000
Q3 2023

Nov 14, 2023

BUY
$0.3 - $1.39 $1,425 - $6,603
4,751 Added 54.73%
13,432 $4,000
Q2 2023

Aug 14, 2023

BUY
$1.12 - $3.76 $35 - $120
32 Added 0.37%
8,681 $11,000
Q1 2023

May 09, 2023

BUY
$1.14 - $2.91 $2,347 - $5,991
2,059 Added 31.24%
8,649 $20,000
Q4 2022

Feb 10, 2023

BUY
$1.15 - $2.12 $2,217 - $4,087
1,928 Added 41.36%
6,590 $8,000
Q3 2022

Nov 10, 2022

BUY
$1.62 - $2.76 $2,629 - $4,479
1,623 Added 53.41%
4,662 $8,000
Q2 2022

Aug 15, 2022

BUY
$2.08 - $4.15 $1,801 - $3,593
866 Added 39.85%
3,039 $7,000
Q1 2022

May 12, 2022

SELL
$2.27 - $5.45 $1,296 - $3,111
-571 Reduced 20.81%
2,173 $7,000
Q4 2021

Feb 14, 2022

BUY
$5.28 - $15.2 $14,488 - $41,708
2,744 New
2,744 $15,000
Q3 2021

Nov 15, 2021

SELL
$10.49 - $24.19 $6,115 - $14,102
-583 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$11.18 - $22.95 $6,517 - $13,379
583 New
583 $6,000

Others Institutions Holding TPST

About Tempest Therapeutics, Inc.


  • Ticker TPST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,418,900
  • Market Cap $9.17M
  • Description
  • Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...
More about TPST
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.